New heart failure drug HJB647 enters early safety testing

NCT ID NCT07465653

Recruiting now Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 19, 2026 · Updated 11 times

Summary

This early-stage study tests the safety and tolerability of a new drug called HJB647 in 12 adults with stable heart failure and reduced pumping ability. Participants will receive two different doses of the drug or a placebo in a crossover design. The goal is to see if the drug is safe and how it moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Jacksonville Center for Clinical
RECRUITING

Jacksonville, Florida, 32216, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nature Coast Clinical Research LLC
RECRUITING

Inverness, Florida, 34452, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Synergy Healthcare
RECRUITING

Bradenton, Florida, 34208, United States

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEART FAILURE WITH REDUCED EJECTION FRACTION